May 1, 2001 | NEWS
This is an approximate transcript (i.e. from notes, not a tape) of an interview between Novazyme and the International Pompe Association (IPA). The participants were, from Novazyme: John Crowley (CEO), Julie Anne Smith (Senior Director, Patient Advocacy), William...
Mar 31, 2001 | NEWS
The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the AGSD-UK (Association for GlycogenA stored form of sugar used for energy. More Storage Disease-United Kingdom. Kevin O’Donnell...
Mar 30, 2001 | NEWS
Excerpt from Pharming Press Release—March 30, 2001 LEIDEN, the Netherlands, March 30, 2001 – Pharming Group N.V. announced the start of a Phase II-III clinical trialA research study that tests new treatments or approaches in people. More of an enzymeA protein...
Mar 21, 2001 | NEWS
Excerpt From Press Release-March 20, 2001 CAMBRIDGE, MA and LEIDEN,the Netherlands—Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., and Pharming Group N.V. (AEX: PHAR and EASDAQ: PHAR) announced the publication March 20 in Genetics in Medicine...
Mar 1, 2001 | NEWS
The following is a transcript of a telephone interview conducted for the IPA(International Pompe Association) by Kevin O’Donnell of the AGSD-UK (Association for Glycogen Storage Disease-United Kingdom. Kevin O’Donnell interviewed Paul Kaplan, General Manager of the...
Oct 6, 2000 | NEWS
Excerpt From Press Release—October 5, 2000 Genzyme General and Pharming Group N.V., announced today that results from the first two clinical trialsA research study that tests new treatments or approaches in people. More ever conducted for Pompe diseaseA rare genetic...
Oct 4, 2000 | NEWS
Chen focused on the phase I/II trials underway at Duke with 3 IIa infants. Average age at diagnosis is 5 months and survival thereafter is 3 1/2 months on average, with a range of 0-9 months. Very few baby’s survive a year. Recombinant enzymeA protein that helps the...
Oct 1, 2000 | NEWS
Genzyme Corporation and it’s development partner, Pharming N.V., are committed to providing an effective and practical therapy for Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More that can be...
Jul 30, 2000 | NEWS
The Lancet—July 29, 2000 Recombinant human alpha-glucosidase from rabbit milk in Pompe patients Lancet 2000; 356: 397-398 Hannerieke Van den Hout, Arnold J J Reuser, Arnold G Vulto, M Christa B Loonen, Adri Cromme-Dijkhuis, Ans T Van der Ploeg Following is a short...
Apr 20, 2000 | NEWS
Genzyme and Pharming to Fund Commercialization Cambridge, Mass., USA, Durham, N.C., USA, and Leiden, the Netherlands, April 19, 2000 – Genzyme General and Synpac (North Carolina) today announced an agreement under which Genzyme will obtain exclusive, worldwide...
